This week's FierceBiotech is brought to you by TD2.

Trouble viewing? Click here.

Preclinical

The Case for Early DMPK
Analysis in Preclinical Research

Strong upfront study design should always consider drug metabolism and pharmacokinetic analysis (DMPK). Years of conducting DMPK studies sooner, rather than later, has proven that discontinuing compounds that may fail in later development strengthens the opportunity for better results.

DMPK Guidelines

Smarter, more effective DMPK studies should be built into your preclinical research strategy using these guidelines:

  1. The earlier the DMPK analysis the better.

    DMPK analysis directly contributes to reduced drug attrition later in drug development. For optimal results, run DMPK studies as early as possible within your drug testing funnel. This can help evaluate whether or not the compound has fundamental metabolic or pharmacokinetic liabilities that could limit future development.

  2. Find and employ the right mix of assays.

    Among parameters such as metabolism, permeability, protein binding or more, ample options await researchers as they employ the right mix of high-throughput assays for DMPK studies. To find yours, assess your study goals and align selected DMPK assays with your preclinical strategy.

  3. Evolve and adapt for optimum success.

    As new drug classes and targets emerge, account for those advancements with adjustments to DMPK parameters to ensure that important factors like additive toxicity or drug-drug interactions don't go untested.

Contact Us

Ready to better results with your DMPK analysis?

Get the peace-of-mind of working with a partner who navigates the DMPK complexities of drug discovery to guide you down a clearly defined path for earlier, more complete results. As a TD2 client, you will have access to a wide variety of DMPK assays, along with expert counsel to help you select the right mix for your new medicines.

Contact us to get started today.

get started

Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered

THE PRECISION ONCOLOGY CRO™ Connect with us on LinkedIn www.td2inc.com

 

If you no longer wish to receive communications from TD2, please opt out here.


Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036